Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1775 Potential Therapeutic Targets for Gastric Poorly Differentiated Neuroendocrine Carcinoma

Introduction: Gastric poorly differentiated neuroendocrine carcinoma (G-PDNEC) is rare and aggressive. Patients often present with distant metastases at initial diagnosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: JI Y

Authors: Ji Y, Xie Y, Chen K, Zeng H, Sun Y,

Keywords: gastric, neuroendocrine carcinoma, mTOR pathway, SSTR, targeted therapies,

#1688 Pancreatic NET-G3 Does Not Respond to Platinum-Based Chemotherapy: A Multicenter Study of Neuroendocrine Carcinomas

Introduction: Recent studies　have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hijioka S

Authors: Hijioka S, Hosoda W, Matsuo k, Ueno M, Furukawa M,

Keywords: NET G3, NEC, KRAS, Rb,

#1687 Pancreatic well-differentiated neuroendocrine tumor with grade 3 does not respond to platinum-based chemotherapy: a multicenter study of neuroendocrine carcinomas

Introduction: Recent studies　have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hijioka S

Authors: Hijioka S,

Keywords: NET-G3, NEC, KRAS, Rb,

#1290 PD-L1 Expression is Associated with Grade of Neuroendocrine Tumors

Introduction: Neuroendocrine neoplasms are divided into well-differentiated neuroendocrine tumors (WDNETs) and poorly differentiated neuroendocrine carcinomas (PDNECs).The correlation between Gastroenteropancreatic Neuroendocrine Neoplasms (GEPNENs) and immunocheck point molecule-PD-L1 is still unclear now.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Leng J

Authors: Li Z, Leng J, Wang H, Li S, Lu M,

Keywords: PD-L1, neuroendocrine tumor, grade,

#620 Multicenter Retrospective Analysis of Systemic Chemotherapy for Advanced Poorly Differentiated Neuroendocrine Carcinoma of Digestive System

Introduction: No standard chemotherapy is established for advanced poorly differentiated neuroendocrine carcinoma (PDNEC) originating from the gastrointestinal tract (GI) or the hepato-biliary-pancreatic system (HBP).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Tomohiro Y

Authors: Yamaguchi T, Machida N, Kasuga A, Takahashi H, Sudo K,

Keywords: poorly-differentiated, PDNEC, irinotecan, etoposide, gastrointestinal,